COX-2 inhibitors and cardiovascular risk

British Journal of Cardiology

Volumn 10, Issue 4, 2003, Pages 288-292

  Schachter, Mike ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular risk; Cyclo oxygenase 2 inhibitors; Non steroidal anti inflammatory drugs; Renal toxicity; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN; ROFECOXIB;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BRONCHOSPASM; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIGESTIVE SYSTEM PERFORATION; DRUG EFFECT; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG SYNTHESIS; DYSPEPSIA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY PAPILLA NECROSIS; META ANALYSIS; NEPHROTOXICITY; NONHUMAN; PEPTIC ULCER; RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOGENESIS;

EID: 0042194546     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. L Biscarini. Non-steroidal anti-inflammatory drugs. In: Dukes MNG, Aronson JK (eds.). Meyler's Side-Effects of Drugs. Amsterdam: Elsevier, 2000, 246-309.
2. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971;231:232-5.
3. Smith W, Garavito R, De Witt D. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and 2. J Biol Chem 1996;271:33157-60.
4. Frölich JC. A classification of NSAIDs according to the relative inhibition of cyclkooxygenase isoenzymes. Trends Pharmacol Sci 1997;18:30-4.
5. Jüni P, Rutjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002;324:1287-8.
6. Jones R. Efficacy and safety of COX 2 inhibitors. BMJ 2002;325:607-08.
7. Wright JM. The double-edged sword of COX-2 selective NSAIDs. Canadian Medical Association Journal 2002;167:1131-7.
8. Harris RC. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 2002;89 (suppl):10D-17D.
9. Komers R, Anderson S, Epstein M. Renal and cardiovascular effects of selective cyclooxygenases-2 inhibitors. Am J Kidney Dis 2001;38:1145-57.
10. Harris RC. Cyclooxygenase 2 inhibition and renal physiology. Am J Cardiol 2002;89(suppl):10D-17D.
11. Patrignani P, Sciulli MG, Manarini S, Santini G, Cerletti C, Evangelista V. COX-2 is not involved in thromboxane synthesis by activated human platelets. J Physiol Pharmacol 1999;50:661-7.
12. Catella-Lawson F, Crofford LJ. Cyclooxygenase and thrombogenicity. Am J Med 2001;110 (3A):28S-32S.
13. Qi Z, Hao C-M, Langenbach RI et al. Opposite effects of cyclooxygenases-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest 2002;110:61-9.
14. MacRae FL, Fazio S. Cyclooxygenase-2 and atherosclerosis. Curr Opin Lipidol 2002;13:497-504.
15. Bing RJ, Lomnicka M. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events? J Am Coll Cardiol 2002;39:521-2.
16. Howes LG, Krum H. Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: How strong is the link? Drug Saf 2002;25:829-35.
17. Pitt B, Pepine C, Willerson JT. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation 2002;106:167-9.
18. Whelton A, White WB, Bello AE, Puma JA, Fort JG. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002;90:959-63.
19. White WB, Kent J, Taylor A, Verburg KM, Lefkowith JB, Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002;39:929-34.
20. Pitkala KH, Strandberg TE, Tilvis RS. Worsening heart failure associated with COX-2 inhibitors. Am J Med 2002;112:424-6.
21. Mukherjee D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem Pharmacol 2002;63:817-21.
22. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
23. Konstam MA, Weir MR, Reicin A et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280-8.
24. Ray WA, Stein M, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and the risk of serious coronary heart disease. Lancet 2002;360:1071-3.
25. Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective non-steroidal anti-inflammatory drugs (ibuprofen, diclofenac, nabumetone). Am J Cardiol 2002;89:204-09.
26. Day R. Another selective COX-2 inhibitor: More questions than answers? J Rheumatol 2002;29:1581-2.
27. Warner TD, Mitchell JA, Vane JR. Cyclo-oxygenase-2 inhibitors and cardiovascular events. Lancet 2002;360:1700.
28. Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: Acute phase related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002;4:R5.
29. Catella-Lawson F, Reilly MP, Kappor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
30. Quellet M, Riendeau D, Percival MD. A high level of cyclooxygenases-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 activity by aspirin. Proc Natl Acad Sci USA 2001;98:14583-8.
31. Curhan GC, Willett WC, Rosner B, Stampfer MJ. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med 2002;162:2204-08.
32. Chandrasekharan NV, Dai H, Roos KLT et al. COX-3, a cyclooxygenases-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, and expression. Proc Natl Acad Sci USA 2002;99:13926-31.
33. Mamdami M, Rochon P, Juurlink DN et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163:481-6.
34. DeMaria AN, Weir MR. Coxibs-beyond the GI tract: Renal and cardiovascular issues. J Pain Symptom Manage 2003;25S:S41-S49.